Brief: Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial Of Tilsotolimod + Ipilimumab In Anti-PD-1 Refractory Advanced Melanoma

Aceragen

18/03/2021 21:35

March 18 (Reuters) - Idera Pharmaceuticals Inc  IDRA.O :
    * IDERA PHARMACEUTICALS ANNOUNCES RESULTS FROM
ILLUMINATE-301
TRIAL OF TILSOTOLIMOD + IPILIMUMAB IN ANTI-PD-1 REFRACTORY
ADVANCED MELANOMA
    * IDERA PHARMACEUTICALS - PLANS ITS ILLUMINATE-206 PHASE 2
STUDY
OF TILSOTOLIMOD IN COMBINATION WITH IPILIMUMAB AND NIVOLUMAB IN
PATIENTS WITH MSS-CRC
    * IDERA PHARMACEUTICALS - REGISTRATION TRIAL OF TILSOTOLIMOD
DID
NOT MEET ITS PRIMARY ENDPOINT OF OBJECTIVE RESPONSE RATE
    * IDERA PHARMACEUTICALS INC - ALTHOUGH PRIMARY ENDPOINT OF
ORR WAS
NOT MET, IF STUDY CONTINUES AND REACHES A POSITIVE OS OUTCOME

Source text for Eikon:  ID:nGNXbBjds5 
Further company coverage:  IDRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))